Advertisement

International Journal of Clinical Pharmacy

, Volume 39, Issue 3, pp 522–526 | Cite as

Use and safety of denosumab in cancer patients

  • Alba ManzanequeEmail author
  • Cristian Chaguaceda
  • Mireia Mensa
  • Carla Bastida
  • Natàlia Creus-Baró
Short Research Report

Abstract

Background Few data have been reported on the use and safety of denosumab in patients with solid tumors and bone metastasis in clinical practice. Objectives To describe the use of denosumab and to analyze its adverse effects (AE) in tertiary hospital cancer outpatients. Methods Retrospective study of patients who started denosumab between January 2013 and June 2015. We recorded demographic, clinical, and treatment-related variables, as well as the reasons for discontinuation and AE. Results The study population comprised 104 patients, of whom 86 (82.7%) were receiving concomitant outpatient cancer treatment and 39 (38%) had previously received zoledronate. At baseline, albumin-corrected calcium levels were available for 48 patients (46.2%), and 70 (67.3%) were receiving calcium/vitamin D supplements. The median number of denosumab doses was 7.5 (range, 1–29). The main reasons for treatment discontinuation were disease progression (20.2%) and AE (25%). Hypocalcaemia was recorded in 38.5% of patients and osteonecrosis of the jaw in 12.5%. Monitoring of calcium levels was poor at baseline and during follow-up. Conclusions We found a higher incidence of all-grade osteonecrosis of the jaw than reported in the literature. Adherence to published recommendations on calcium supplementation and guidelines on calcium monitoring was poor. In line with our findings, a protocol for use and monitoring of denosumab has been promoted in our hospital.

Keywords

Calcium monitoring Denosumab Hypocalcemia Osteonecrosis 

Notes

Funding

The authors declare that no funding was received for the present study.

Conflicts of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, et al. Guidance on the use of bisphosphonates in solid tumors: recommendations of an international expert panel. Ann Oncol. 2008;19(3):420–32.CrossRefPubMedGoogle Scholar
  2. 2.
    Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, De Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, doubleblind study. Lancet. 2011;377(9768):813–22.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    European Medicines Agency. Xgeva (denosumab) summary of product characteristics. http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002173/WC500110381.pdf. Accessed 10 Jan 2016.
  5. 5.
    Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, et al. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer. 2016;24(1):447–55.CrossRefPubMedGoogle Scholar
  6. 6.
    Ford JA, Jones R, Elders A, Mulatero C, Royle P, Sharma P, et al. Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis. Eur J Cancer. 2013;49(2):416–30.CrossRefPubMedGoogle Scholar
  7. 7.
    Qi WX, Lin F, He AN, Tang LN, Shen Z, Yao Y. Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies. Curr Med Res Opin. 2013;29(9):1067–73.CrossRefPubMedGoogle Scholar
  8. 8.
    United States, National Institutes of Health, National Cancer Institute, Cancer Therapy Evaluation Program (CTEP). Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.Google Scholar
  9. 9.
    Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23:1341–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Watkins KR, Rogers JE, Atkinson B. Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency. Support Care Cancer. 2015;23(6):1657–62.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing 2017

Authors and Affiliations

  • Alba Manzaneque
    • 1
    Email author
  • Cristian Chaguaceda
    • 1
  • Mireia Mensa
    • 1
  • Carla Bastida
    • 1
  • Natàlia Creus-Baró
    • 1
  1. 1.Pharmacy DepartmentHospital Clinic de BarcelonaBarcelonaSpain

Personalised recommendations